History

Navidea Biopharmaceuticals was founded as Neoprobe Corporation in 1983. With the sale of the neoprobe®GDS medical device business in 2011, Navidea Biopharmaceuticals was born. This event aimed to give Navidea management greater strategic flexibility to drive long-term earnings growth and shareholder return. The Company's transformation into a biopharmaceutical company is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. Below is a detailed timeline of significant events in our 26 year history demonstrating the considerable energy with which we approach our business.

1983

  • Neoprobe incorporated in Ohio

1988

  • Neoprobe reincorporated in Delaware

1992

  • Initial public offering

1998

  • neo2000 Gamma detection device launched
  • Temporary suspension of RIGS® (radioimmunoguided surgery) development

2002

  • Expansion of the medical device business

2004

  • Initial corporate development of Lymphoseek® radiopharmaceutical

2006

  • Introduction of wireless gamma detection probes

2008

  • neoprobe GDS control console introduced
  • Wireless laparoscopic probe introduced

2009

  • High energy probe introduced

2011

  • Positive Phase III results for Lymphoseek in intraoperative lymphatic mapping reported
  • Sale of the neoprobeGDS product line to Devicor Medical Products
  • Submission of Lymphoseek imaging agent New Drug Application to the FDA
  • Announced Neoprobe Corporation name change to Navidea BioPharmaceuticals
  • In-licensing of AstraZeneca radiopharmaceutical imaging agent, AZD4694, aiding in the diagnosis for Alzheimer’s disease

2012

  • Change of NYSE Amex stock ticker from NEOP to NAVB

2013

  • Lymphoseek® (technetium Tc 99m tilmanocept) Injection approved by the US FDA

2014

  • Lymphoseek sNDA approved for guiding Sentinel Lymph Node (SLN) Biopsy in certain head and neck cancers
  • Lymphoseek received Orphan Drug designation in US for head and neck cancers
  • Lymphoseek received European approval in SLN detection for melanoma, breast and certain head and neck cancers.
  • Lymphoseek sNDA approved for lymphatic mapping of all solid tumors and added guiding SLN Biopsy indication for breast cancer and melanoma